Columbia University Medical Center
New York, 10032, United States
Location status: Recruiting
NCT Number: NCT03372317
The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.
Interested in participating?
Request Info55 year–90 year
All sexes
Observational
New York, 10032, United States
Location status: Recruiting
Many cognitively healthy older adults have, upon post mortem evaluations, been found to have varying amounts of neurofibrillary tangles (tau) and beta-amyloid plaque deposits, which are the hallmark brain pathologies known to be associated with Alzheimer's disease and various other dementias. While some with these pathologies may not clinically express cognitive decline or dementia in their lifetime, human post-mortem studies suggest that increasing neurofibrillary tangle density correlates with neurodegeneration and cognitive impairment.
Imaging tauopathy in-vivo provides an opportunity to examine neurocognitive correlates of differential levels of tauopathy in the brain, allowing to further qualify pre-clinical states of cognitive impairment. The investigators aim to investigate possible protective mechanisms, such as cognitive reserve, that may modulate the relationship between tauopathy and cognitive decline.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Results of the 18F-MK-6240 PET scan will be correlated with other observations.
Other names: 6-[18F]Fluoro-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine
Time frame: Up to 5 years
Based on the scans, the total number of subjects with identifiable tau in their scans will be measured.
Time frame: Up to 5 years
Relation of Tau PET to measures of cognition such as memory and reasoning
Time frame: Up to 5 years
Relation of Tau PET to imaging acquired during task performance
Contact information is provided by the study sponsor or research team.
Yaakov Stern
Other
Tau Positron Emission Tomography (PET) in Imaging and Cognition
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03174938
ALS (Amyotrophic Lateral Sclerosis), Alzheimer Disease
Ängelholm, Sweden
View Trial DetailsNCT05929703
Aging, Alzheimer Disease
Orange, California, United States
View Trial DetailsNCT03507257
Alzheimer Disease, Brain Diseases
Sun City, Arizona, United States
View Trial DetailsNCT05372172
Aging, Alzheimer Disease
Nashville, Tennessee, United States
View Trial Details